Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636256 · ClinicalTrials.gov registry record · Phase 1
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
A Phase 1 study, sponsored by NanOlogy.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03636256: Completed Phase 1 study, sponsored by NanOlogy.
NCT03636256 is a Phase 1 study that has completed, run by NanOlogy. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03636256, a Phase 1 study, has completed, sponsored by NanOlogy.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation. All participants will receive NanoDoce, and will be evaluated for safety and tolerability, as well as the potential effects of NanoDoce on urothelial carcinoma.
Primary Outcome
Treatment Emergent Adverse Events included laboratory assessments, physical examination findings, and vital signs.
Interventions
- DRUG NanoDoce (direct injection)
- DRUG NanoDoce (intravesical instillation) - Visit 2 Instillation
- OTHER Institutional Standard of Care
- DRUG NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-04-02 |
| Est. Completion | 2021-11-02 |
| Phase | Phase 1 |
What the finished NCT03636256 record still lists
NCT03636256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 4 interventions - of which NanoDoce (direct injection) is the first listed.
NCT03636256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03636256 about?
NCT03636256 is a clinical study titled "Evaluation of NanoDoce® in Participants With Urothelial Carcinoma". This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation. All participants will receive NanoDoce, and will be evaluated for safety and tolerability, as well as the potential effect...
What is the current status of trial NCT03636256?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2019-04-02. Estimated completion is 2021-11-02.
What interventions are being tested in trial NCT03636256?
The interventions under investigation include: NanoDoce (direct injection) (DRUG), NanoDoce (intravesical instillation) - Visit 2 Instillation (DRUG), Institutional Standard of Care (OTHER), NanoDoce (intravesical instillation) - Induction and Maintenance Instillations (DRUG).
Who is sponsoring clinical trial NCT03636256?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03636256's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI